A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
← catalyst calendarNCT05777993 · readout ≤ 1,108 d
Sponsored by Agios Pharmaceuticals, Inc. (industry) · AGIO — their whole pipeline →.
Phase
Phase 4
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
59estimated
Sites
23
Countries
Belgium, Brazil, Canada +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-06 | actual | When the study began enrolling |
| Primary completion | Aug 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pyruvate Kinase Deficiency
- Anemia, Hemolytic
- Sickle Cell Disease
- Thalassemia
Intervention
- Drug: Mitapivat — also filed as AG-348, Mitapivat sulfate
Primary outcome
what the primary-completion date above is the date OFNot applicable as this protocol is to provide an option for continued access to mitapivat for participants who have previously participated in an Agios-sponsored mitapivat study
measured Not Applicable - Study Completion
Permalink · AGIO's whole pipeline · Catalyst calendar · Every registered study · What changed